Novel diamides inspired by protein kinase inhibitors as anti-Trypanosoma cruzi agents: in vitro and in vivo evaluations.

Background: Chagas disease is a life-threatening illness caused by Trypanosoma cruzi. The involvement of serine-arginine-rich protein kinase in the T. cruzi life cycle is significant. Aims: To synthesize, characterize and evaluate the trypanocidal activity of diamides inspired by kinase inhibitor, SRPIN340. Material & Methods: Synthesis using a three-step process and characterization by infrared, nuclear magnetic resonance and high-resolution mass spectrometry were conducted. The selectivity index was obtained by the ratio of CC50/IC50 in two in vitro models. The most active compound, 3j, was evaluated using in vitro cytokine assays and assessing in vivo trypanocidal activity. Results: 3j activity in the macrophage J774 lineage showed an anti-inflammatory profile, and mice showed significantly reduced parasitemia and morbidity at low compound dosages. Conclusion: Novel diamide is active against T. cruzi in vitro and in vivo.

[1]  G. Bressan,et al.  Immunomodulatory activity of trifluoromethyl arylamides derived from the SRPK inhibitor SRPIN340 and their potential use as vaccine adjuvant. , 2022, Life sciences.

[2]  M. Rodríguez-Sosa,et al.  Characterisation of Macrophage Polarisation in Mice Infected with Ninoa Strain of Trypanosoma cruzi , 2021, Pathogens.

[3]  P. Gong,et al.  SRPK1/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-κB activation in colon cancer , 2021, Journal of translational medicine.

[4]  Ana L. M. Karl,et al.  Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants , 2021, Scientific Reports.

[5]  Clement Agoni,et al.  Druggability and drug-likeness concepts in drug design: are biomodelling and predictive tools having their say? , 2020, Journal of Molecular Modeling.

[6]  S. Gea,et al.  Signaling pathways that regulate Trypanosoma cruzi infection and immune response. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[7]  A. L. Mazzeti,et al.  Benznidazole Self-Emulsifying Delivery System: A Novel Alternative Dosage Form For Chagas Disease Treatment. , 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  I. Molina,et al.  Serum IL-10 Levels and Its Relationship with Parasitemia in Chronic Chagas Disease Patients. , 2019, The American journal of tropical medicine and hygiene.

[9]  F. Villalta,et al.  Advances in preclinical approaches to Chagas disease drug discovery , 2019, Expert opinion on drug discovery.

[10]  M. C. Brelaz-de-Castro,et al.  Chagas Disease Treatment and Rational Drug Discovery: A Challenge That Remains , 2019, Front. Pharmacol..

[11]  Jian Huang,et al.  SRPIN340 protects heart muscle from oxidative damage via SRPK1/2 inhibition-mediated AKT activation. , 2019, Biochemical and biophysical research communications.

[12]  Paola Acosta‐Guzmán,et al.  Direct Transamidation Reactions: Mechanism and Recent Advances , 2018, Molecules.

[13]  M. Renuka,et al.  Synthesis of secondary amides by direct amidation using polymer supported copper(II) complex , 2018, Polyhedron.

[14]  G. Bressan,et al.  Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs). , 2017, European journal of medicinal chemistry.

[15]  R. López-Vélez,et al.  Challenges in the management of Chagas disease in Latin-American migrants in Europe. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  É. Ferreira,et al.  Predominance of Th1 response, increase of megakaryocytes and Kupffer cells are related to survival in Trypanosoma cruzi infected mice treated with Lycopodium clavatum. , 2016, Cytokine.

[17]  Franciele Q. Ames,et al.  Canova medication changes TNF-α and IL-10 serum levels in mice infected with Trypanosoma cruzi Y strain. , 2016, Asian Pacific journal of tropical medicine.

[18]  H. S. Rosenzweig,et al.  Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds , 2016, European journal of medicinal chemistry.

[19]  M. D. Polêto,et al.  Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340) , 2015, PloS one.

[20]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[21]  Alan Talevi,et al.  High-throughput drug repositioning for the discovery of new treatments for Chagas disease. , 2015, Mini reviews in medicinal chemistry.

[22]  E. Chatelain.  Chagas Disease Drug Discovery , 2015, Journal of biomolecular screening.

[23]  Vipin Kumar,et al.  A mini review on pyridoacridines: Prospective lead compounds in medicinal chemistry , 2014, Journal of advanced research.

[24]  J. Oxley,et al.  SERINE ARGININE PROTEIN KINASE-1 (SRPK1) INHIBITION AS A POTENTIAL NOVEL TARGETED THERAPEUTIC STRATEGY IN PROSTATE CANCER , 2014, Oncogene.

[25]  M. Miles,et al.  Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity , 2014, Memorias do Instituto Oswaldo Cruz.

[26]  D. Bates,et al.  Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma , 2014, British Journal of Cancer.

[27]  M. Eberlin,et al.  Brønsted acid catalyzed azlactone ring opening by nucleophiles , 2014 .

[28]  A. Romanha,et al.  The in vitro activity of fatty diamines and amino alcohols against mixed amastigote and trypomastigote Trypanosoma cruzi forms , 2014, Memorias do Instituto Oswaldo Cruz.

[29]  S. Harper,et al.  SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. , 2013, Investigative ophthalmology & visual science.

[30]  Sephra N. Rampersad,et al.  Multiple Applications of Alamar Blue as an Indicator of Metabolic Function and Cellular Health in Cell Viability Bioassays , 2012, Sensors.

[31]  Ryan M. Plocinik,et al.  The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. , 2012, Molecular cell.

[32]  J. McKerrow,et al.  The Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion , 2011, PLoS pathogens.

[33]  C. Nakamura,et al.  Natural products and Chagas' disease: a review of plant compounds studied for activity against Trypanosoma cruzi. , 2011, Natural product reports.

[34]  E. Nikolakaki,et al.  Serine‐arginine protein kinases: a small protein kinase family with a large cellular presence , 2011, The FEBS journal.

[35]  Rick L. Tarleton,et al.  In Vitro and In Vivo High-Throughput Assays for the Testing of Anti-Trypanosoma cruzi Compounds , 2010, PLoS neglected tropical diseases.

[36]  Z. Yadón,et al.  Chagas disease: a Latin American health problem becoming a world health problem. , 2010, Acta tropica.

[37]  J. Castro,et al.  Toxic Side Effects of Drugs Used to Treat Chagas’ Disease (American Trypanosomiasis) , 2006, Human & experimental toxicology.

[38]  M. Hagiwara,et al.  Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  W. de Souza,et al.  Effects of protein kinase and phosphatidylinositol-3 kinase inhibitors on growth and ultrastructure of Trypanosoma cruzi. , 2006, FEMS microbiology letters.

[40]  A. Gómez-Barrio,et al.  Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes , 2006, Parasitology Research.

[41]  M. Parsons,et al.  Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi , 2005, BMC Genomics.

[42]  Hisami Ikeda,et al.  Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. , 2003, Pharmacology & therapeutics.

[43]  T. Souto-Padrón,et al.  Cellular signaling during the macrophage invasion by Trypanosoma cruzi , 2002, Histochemistry and Cell Biology.

[44]  R. Gazzinelli,et al.  Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. , 2002, The Journal of infectious diseases.

[45]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[46]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[47]  Murta,et al.  In‐vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug‐susceptible but not with a derived drug‐resistant Trypanosoma cruzi population , 1999, Parasite immunology.

[48]  W. de Souza,et al.  Effect of protein kinase inhibitors on the invasion process of macrophages by Trypanosoma cruzi. , 1994, Biochemical and biophysical research communications.

[49]  Xiang-Dong Fu.  Specific commitment of different pre-mRNAs to splicing by single SR proteins , 1993, Nature.

[50]  L. Filardi,et al.  Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[51]  OUP accepted manuscript , 2021, Nucleic Acids Research.

[52]  B. Spellberg,et al.  Type 1/Type 2 immunity in infectious diseases. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.